AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23385197 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 1895
Study 23385985 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexpanded perforator flaps (thoracodorsal artery perforator, intercostal artery perforator, circumflex scapular artery perforator)
Number of subjects: 7
Study 23385985 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexpanded perforator flaps
Number of subjects: 7
Study 23386371 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 12
Study 23388195 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H1N1 pandemic vaccine
Number of subjects: 9143
Study 23388350 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-informed nursing management
Number of subjects: 424
Study 23388405 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h systolic blood pressure variability (SBP)
Number of subjects: 344
Study 23388405 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h diastolic blood pressure variability (DBP)
Number of subjects: 344
Study 23388405 — intervention group
Group type: EXPERIMENTAL
Intervention: CV of awake DBP
Number of subjects: 344
Study 23388405 — intervention group
Group type: EXPERIMENTAL
Intervention: CV and SD of 24-h and awake SBP/DBP
Number of subjects: 344
Study 23388405 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h DBP
Number of subjects: 344
Study 23388405 — intervention group
Group type: EXPERIMENTAL
Intervention: SD and CV for vascular damage
Number of subjects: 344
Study 23388405 — intervention group
Group type: EXPERIMENTAL
Intervention: BPV (24-h, awake and sleep)
Number of subjects: 344
Study 23388559 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy (54 Gy in 1.8 Gy per fraction)
Number of subjects: 23
Study 23388612 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine [TIMP-2]·[IGFBP7]
Number of subjects: 728
Study 23388612 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine insulin-like growth factor-binding protein 7 (IGFBP7)
Number of subjects: 728
Study 23388612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue inhibitor of metalloproteinases-2 (TIMP-2)
Number of subjects: 728
Study 23388612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-variable clinical model with [TIMP-2]·[IGFBP7] added
Number of subjects: 728
Study 23388612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses with [TIMP-2]·[IGFBP7]
Number of subjects: 728
Study 23390496 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine monotherapy (600 mg once-daily)
Number of subjects: 100
Study 23390496 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine plus tenofovir (300 mg once-daily)
Number of subjects: 100
Study 23391088 — intervention group
Group type: EXPERIMENTAL
Intervention: Assurant cobalt chromium balloon-expandable stent system
Number of subjects: 123
Study 23391200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative plasma GDF-15 levels
Number of subjects: 1458
Study 23391200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of GDF-15 and additive EuroSCORE
Number of subjects: 1458
Study 23391200 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of GDF-15 ≥1.8 ng/ml
Number of subjects: 1458
Study 23391200 — intervention group
Group type: COMPARATOR
Intervention: Presence of NTproBNP (cutoff ≥2,000 pg/ml) or hsTNT (cutoff 14 pg/ml)
Number of subjects: 1458
Study 23391248 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative systemic polychemotherapy including cetuximab, cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC) with intraperitoneal oxaliplatin
Number of subjects: 60
Study 23391586 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-sodium fluoride (18F-NaF) for calcification
Number of subjects: 101
Study 23391586 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-fluorodeoxyglucose (18F-FDG) for inflammation
Number of subjects: 101
Study 23391586 — intervention group
Group type: COMPARATOR
Intervention: Calcium scores
Number of subjects: 101
Study 23391616 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (2.3 mg/m(2)/d) and bevacizumab (15 mg/kg) combination treatment
Number of subjects: 50
Study 23391616 — intervention group
Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 50
Study 23392444 — intervention group
Group type: EXPERIMENTAL
Intervention: 15° reverse Trendelenburg position
Number of subjects: 51
Study 23392444 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 51
Study 23392444 — intervention group
Group type: EXPERIMENTAL
Intervention: 15° Trendelenburg position
Number of subjects: 51
Study 23392444 — intervention group
Group type: COMPARATOR
Intervention: Comparison of reverse Trendelenburg to supine
Number of subjects: 51
Study 23392444 — intervention group
Group type: COMPARATOR
Intervention: Comparison of supine to Trendelenburg
Number of subjects: 51
Study 23392444 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg positioning
Number of subjects: 51
Study 23392467 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir without tenofovir (300/100 mg during second trimester, 400/100 mg during third trimester, 300/100 mg postpartum)
Number of subjects: 72
Study 23392467 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir with tenofovir (300/100 mg during second trimester, 400/100 mg during third trimester, 300/100 mg postpartum)
Number of subjects: 72
Study 23392654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 565
Study 23392654 — intervention group
Group type: COMPARATOR
Intervention: A-allele carriers of rs12041331
Number of subjects: 565
Study 23392654 — intervention group
Group type: COMPARATOR
Intervention: A-allele carriers of rs12041331 in aspirin-treated INVEST-GENES patients
Number of subjects: 565
Study 23393050 — intervention group
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate
Number of subjects: 54
Study 23393105 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium bicarbonate (NaHCO3) at doses of 0.3, 0.6, and 1.0 mEq/kg per day
Number of subjects: 20
Study 23393105 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium bicarbonate (NaHCO3)
Number of subjects: 20
Study 23393169 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys with long CAG repeats (CAG ≥ 24)
Number of subjects: 78
Study 23393169 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys with short CAG repeats (CAG 17-20)
Number of subjects: 78
Study 23393196 — intervention group
Group type: EXPERIMENTAL
Intervention: JX-594 treatment
Number of subjects: 0
Study 23394586 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures
Number of subjects: 148
Study 23394586 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 148
Study 23394586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 148
Study 23394629 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2
Number of subjects: 24
Study 23394838 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 40
Study 23394966 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental restriction and family pressure to be thin
Number of subjects: 90
Study 23394966 — intervention group
Group type: EXPERIMENTAL
Intervention: Media pressure
Number of subjects: 90
Study 23394966 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance orientation and preoccupation with becoming overweight
Number of subjects: 90
Study 23395076 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 206
Study 23395076 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio) at rest
Number of subjects: 206
Study 23395076 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio) with hyperemia
Number of subjects: 206
Study 23395076 — intervention group
Group type: COMPARATOR
Intervention: FFR (fractional flow reserve)
Number of subjects: 206
Study 23395934 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing galectin-3 levels over time (from low to high category)
Number of subjects: 1653
Study 23395934 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 increase >15% between measurements
Number of subjects: 1653
Study 23395934 — intervention group
Group type: COMPARATOR
Intervention: Stable or decreasing galectin-3 levels
Number of subjects: 1653
Study 23396491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) nicorandil 2 mg
Number of subjects: 210
Study 23396491 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) adenosine infusion (140 μg/kg/min)
Number of subjects: 210
Study 23396491 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary (IC) adenosine
Number of subjects: 210
Study 23396491 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) adenosine
Number of subjects: 210
Study 23396491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) nicorandil
Number of subjects: 210
Study 23396494 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy
Number of subjects: 1415
Study 23396494 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 1415
Study 23396557 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine iron (n=2184; 60 mg ferrous sulfate plus 400 μg of folic acid daily throughout pregnancy)
Number of subjects: 4326
Study 23396557 — intervention group
Group type: COMPARATOR
Intervention: Selective iron (n=2142; screening and treatment for anaemia and daily intake of 1 mg of folic acid)
Number of subjects: 4326
Study 23398615 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandmothers, Aunts, Female Family Friends
Number of subjects: 159
Study 23398615 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandmothers, Fathers
Number of subjects: 159
Study 23398615 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Parenting
Number of subjects: 159
Study 23398640 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP (25, 50, or 75 U kg(-1))
Number of subjects: 26
Study 23398640 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP (50 U kg(-1))
Number of subjects: 26
Study 23398640 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP
Number of subjects: 26
Study 23398660 — intervention group
Group type: EXPERIMENTAL
Intervention: Video capsule endoscopy (Pillcam Eso2; Given Imaging)
Number of subjects: 25
Study 23398686 — intervention group
Group type: EXPERIMENTAL
Intervention: Prudent dietary pattern (high intakes of vegetables, fruits, whole grain products)
Number of subjects: 210
Study 23398686 — intervention group
Group type: EXPERIMENTAL
Intervention: Western dietary pattern (high intakes of refined grain products, desserts, sweets, and processed meats)
Number of subjects: 210
Study 23399938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic stone protein
Number of subjects: 91
Study 23399938 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 91
Study 23399938 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 91
Study 23399938 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 91
Study 23399938 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cells (WBCs)
Number of subjects: 91
Study 23400739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib (5-days-on/2-days-off intermittent dosing schedule)
Number of subjects: 0
Study 23400739 — intervention group
Group type: COMPARATOR
Intervention: Dovitinib (continuous daily dosing schedule)
Number of subjects: 0
Study 23401019 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation
Number of subjects: 11
Study 23401248 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid (UA) levels
Number of subjects: 709
Study 23401248 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin and adiponectin (in adults only)
Number of subjects: 709
Study 23401248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuchal and visceral fat measurements
Number of subjects: 709
Study 23401248 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid intima media thickness (IMT)
Number of subjects: 709
Study 23401248 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) criteria
Number of subjects: 709
Study 23401274 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP9 upregulation in bone PCR
Number of subjects: 35
Study 23401274 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP9 upregulation in mucosa PCR
Number of subjects: 35
Study 23401274 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP2 and TIMP1 regulation
Number of subjects: 35
Study 23401274 — intervention group
Group type: COMPARATOR
Intervention: Steroid treatment
Number of subjects: 35
Study 23401442 — intervention group
Group type: EXPERIMENTAL
Intervention: R-BAC (rituximab 375 mg/m(2) IV on day 1, bendamustine 70 mg/m(2) IV on days 2 and 3, cytarabine 800 mg/m(2) IV on days 2 to 4) every 28 days for four to six cycles
Number of subjects: 40
Study 23403011 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridines
Number of subjects: 516
Study 23403011 — intervention group
Group type: COMPARATOR
Intervention: Control (no thienopyridines)
Number of subjects: 516
Study 23403253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine at 0.25-1 mg/kg/dose for 14 days
Number of subjects: 12
Study 23403253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine at 1.5 mg/kg/dose
Number of subjects: 12
Study 23403253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine at 1 mg/kg/dose
Number of subjects: 12
Study 23403253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine at 0.25-1 mg/kg/dose
Number of subjects: 12
Study 23403322 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (24 courses)
Number of subjects: 34
Study 23403322 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived factor VII
Number of subjects: 34
Study 23403322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Number of subjects: 34
Study 23403322 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent courses (three times weekly, n=23)
Number of subjects: 34
Study 23403322 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent courses (≤ 2 times weekly, n=15)
Number of subjects: 34
Study 23403322 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prophylaxis
Number of subjects: 34
Study 23404722 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 328
Study 23404722 — intervention group
Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 328
Study 23406027 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg twice daily)
Number of subjects: 20
Study 23406027 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine therapy
Number of subjects: 20
Study 23406027 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 20
Study 23406163 — intervention group
Group type: EXPERIMENTAL
Intervention: RESMENA diet
Number of subjects: 96
Study 23406163 — intervention group
Group type: COMPARATOR
Intervention: AHA dietary pattern
Number of subjects: 96
Study 23406163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary TAC
Number of subjects: 96
Study 23406538 — intervention group
Group type: EXPERIMENTAL
Intervention: High PAPP-A levels (Q3 and Q4)
Number of subjects: 871
Study 23406538 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin in upper quartile (Q4)
Number of subjects: 871
Study 23406600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonallergic rhinitis (NAR)
Number of subjects: 175
Study 23406688 — intervention group
Group type: COMPARATOR
Intervention: South Asian ethnicity
Number of subjects: 111555
Study 23406688 — intervention group
Group type: COMPARATOR
Intervention: Diabetes in South Asians
Number of subjects: 111555
Study 23406688 — intervention group
Group type: COMPARATOR
Intervention: South Asian ethnicity among diabetics, older people, and those in high deprivation areas
Number of subjects: 111555
Study 23406700 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ET) for 8 weeks (~180 min/wk at 40-55% VO2PeakR)
Number of subjects: 11
Study 23406700 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ET)
Number of subjects: 11
Study 23407305 — intervention group
Group type: EXPERIMENTAL
Intervention: trans-palmitoleate concentrations
Number of subjects: 2617
Study 23408352 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating methylated SEPT9 DNA (mSEPT9)
Number of subjects: 7941
Study 23408352 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without CRC)
Number of subjects: 7941
Study 23409033 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating progranulin levels in subjects with metabolic syndrome
Number of subjects: 127
Study 23409033 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating progranulin levels
Number of subjects: 127
Study 23409033 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum progranulin levels
Number of subjects: 127
Study 23409033 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRP3 concentrations
Number of subjects: 127
Study 23409033 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 and triglyceride levels
Number of subjects: 127
Study 23410147 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy for chronic hepatitis C, specific details not available.
Number of subjects: 0
Study 23410543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress-induced ischemia
Number of subjects: 310
Study 23410543 — intervention group
Group type: COMPARATOR
Intervention: Exercise-induced ischemia
Number of subjects: 310
Study 23411383 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation EGFR TKIs (e.g., afatinib, dacomitinib, XL647, AP26113, CO-1686)
Number of subjects: 0
Study 23411383 — intervention group
Group type: COMPARATOR
Intervention: First-generation EGFR TKIs (e.g., erlotinib, gefitinib)
Number of subjects: 0
Study 23411385 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 0
Study 23411385 — intervention group
Group type: COMPARATOR
Intervention: Active Treatment
Number of subjects: 0
Study 23411428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (20,000 IU weekly for 12-13 weeks)
Number of subjects: 30
Study 23414587 — intervention group
Group type: EXPERIMENTAL
Intervention: MEK162 45 mg for NRAS-mutated melanoma
Number of subjects: 71
Study 23414587 — intervention group
Group type: EXPERIMENTAL
Intervention: MEK162 45 mg for BRAF-mutated melanoma
Number of subjects: 71
Study 23415622 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-P > LDL-C subgroup (n = 375)
Number of subjects: 2384
Study 23415622 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-P < LDL-C subgroup (n = 428)
Number of subjects: 2384
Study 23415622 — intervention group
Group type: COMPARATOR
Intervention: Concordant subgroup (LDL-P ≅ LDL-C)
Number of subjects: 2384
Study 23415641 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF inhibitors
Number of subjects: 0
Study 23416208 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of pathogens by PCR
Number of subjects: 1065
Study 23416208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 1065
Study 23416208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen identification
Number of subjects: 1065
Study 23416644 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 score cutoff of 25
Number of subjects: 466
Study 23416644 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 score less than 25
Number of subjects: 466
Study 23416644 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding PCA3 score to logistic regression model
Number of subjects: 466
Study 23416850 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen (cyclophosphamide 50 mg/kg, fludarabine 150 mg/m(2), thiotepa 10 mg/kg, and 400 cGy total body irradiation with cyclosporine-A/mycophenolate mofetil immunosuppression)
Number of subjects: 30
Study 23416850 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen
Number of subjects: 30
Study 23416852 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative sibling MRD HSCT
Number of subjects: 22
Study 23416852 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity parental haploidentical donor HSCT
Number of subjects: 22
Study 23416852 — intervention group
Group type: COMPARATOR
Intervention: Both MRD and haploidentical donor HSCT
Number of subjects: 22
Study 23417027 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 23417027 — intervention group
Group type: EXPERIMENTAL
Intervention: Activin A-neutralizing antibody
Number of subjects: 0
Study 23417207 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Satisfaction in the ICU (FS-ICU) questionnaire; Quantitative analysis with a summary score of 78.3 ± 14.3 on a scale of 0 to 100.
Number of subjects: 215
Study 23417207 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of open-ended questions; Themes identified for improvement: patient agitation, clarity and completeness of information, emotional support, respect and compassion towards families.
Number of subjects: 215
Study 23417207 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting room, ICU atmosphere, and amenities for visiting relatives; Not explicitly quantified.
Number of subjects: 215
Study 23417339 — intervention group
Group type: EXPERIMENTAL
Intervention: POAG patients
Number of subjects: 146
Study 23417339 — intervention group
Group type: EXPERIMENTAL
Intervention: OHT patients
Number of subjects: 146
Study 23417339 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 146
Study 23417339 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of flicker response to intraocular pressure (IOP)
Number of subjects: 146
Study 23417339 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of flicker response to level of glaucomatous damage
Number of subjects: 146
Study 23417339 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of flicker response between superior and inferior vessels of the same eye
Number of subjects: 146
Study 23417565 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-EGFRI-18 questionnaire
Number of subjects: 10